The overlapping TMA data for TSPAN1 between benign and prostate cancer groups presented in this study do not suggest that detection of TSPAN1 alone could be used clinically, but indicate it may still be worthwhile to examine TSPAN1 levels as part of a ‘tetraspanin signature’ in future studies. This evidence concerns the gene TSPAN1 and prostate cancer.